Who makes Vinorelbine, Cyclophosphamide and Interferon alpha 2b?

Vinorelbine, Cyclophosphamide and Interferon alpha 2b is developed by Institut Paoli-Calmettes.

Last reviewed 2026-05-13 · How we verify

Vinorelbine, Cyclophosphamide and Interferon alpha 2b

Institut Paoli-Calmettes · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	Vinorelbine, Cyclophosphamide and Interferon alpha 2b
Sponsor	Institut Paoli-Calmettes
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b (" Metronomic Chemotherapy ") for Antiangiogenic and Antivascular Effect. Trial With Pharmacodynamic Study in Adult Advanced Neoplasm (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Vinorelbine, Cyclophosphamide and Interferon alpha 2b CI brief — competitive landscape report
Vinorelbine, Cyclophosphamide and Interferon alpha 2b updates RSS · CI watch RSS
Institut Paoli-Calmettes portfolio CI